CoChat

GLP-1 Receptor Agonists and the Thyroid: C-Cell Effects in Mice Are Mediated via the GLP-1 Receptor and not Associated with RET Activation

Open access
Madsen, Lars Wichmann, Knauf, Jeffrey A., Gotfredsen, Carsten, Pilling, Andrew, Sjögren, Ingrid, Andersen, Søren, Andersen, Lene, Sietske de Boer, Anne, Manova, Katia, Barlas, Afsar, Vundavalli, Sushil, Nyborg, Niels C. Berg, Bjerre Knudsen, Lotte, Moelck, Anne Marie, Fagin, James A. · 2012 · Endocrinology

The DOI matches its Crossref record; 27 of the 29 references it cites were found in a registry or an index.

Abstract

Liraglutide and exenatide are glucagon-like peptide receptor (GLP-1R) agonists used in the treatment of type 2 diabetes. Both molecules have been associated with the development of thyroid C-cell tumors after lifetime exposure in rodents. Previously, it has been reported that these tumors are preceded by increased plasma calcitonin and C-cell hyperplasia. We can now document that the murine C-cell effects are mediated via GLP-1R. Thus, 13 wk of continuous exposure to GLP-1R agonists was associated with marked increases in plasma calcitonin and in the incidence of C-cell hyperplasia in wild-type mice. In contrast, similar effects were not seen in GLP-1R knockout mice. Human C-cell cancer is often caused by activating mutations in the rearranged-during-transfection (RET) protooncogene. We developed an immunohistochemical method to assess RET activation in tissues. Liraglutide dosing to mice was not found to activate RET. Further evaluation of the signaling pathways demonstrated that liraglutide increased ribosomal S6, but not MAPK kinase, phosphorylation. These observations are consistent with effects of GLP-1R agonists on rodent C cells being mediated via mammalian target of rapamycin activation in a RET- and MAPK-independent manner.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1210/en.2011-1864

Cites

27 of 27 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 3

  1. DeLellis, 1994, Changes in structure and function of thyroid C-cell, 285
  2. Botts, 1991, Proliferative lesions of the thyroid and parathyroid glands, E-3, 1
  3. Boorman, 1996, C-cell hyperplasia, C-cell adenoma, and C-cell carcinoma, thyroid in rats, 262

Cited by

See all 161

Metadata

Authors
Madsen, L. W., Knauf, J. A., Gotfredsen, C., Pilling, A., Sjögren, I., Andersen, S., Andersen, L., Sietske de Boer, A., Manova, K., Barlas, A., Vundavalli, S., Nyborg, N. C. B., Bjerre Knudsen, L., Moelck, A. M., & Fagin, J. A.
Affiliations
  • Novo Nordisk (Denmark) (DK)
  • Memorial Sloan Kettering Cancer Center (US)
  • Huntingdon Life Sciences (A.P.), Eye, Suffolk, IP23 7PX, United Kingdom
  • Novo Nordisk A/S (L.W.M., C.G., I.S., S.A., L.A., A.S.d.B., N.C.B.N., L.B.K., A.M.M.), Novo Allé, DK-2880, Bagsvaerd, Denmark
  • Memorial Sloan-Kettering Cancer Center (J.A.K., K.M., A.B., S.V., J.A.F.), New York, New York 10065
Corresponding author
  • Madsen, Lars Wichmann
  • Fagin, James A.
Venue
Endocrinology
Published
2012-03-01
Volume
153
Issue
3
Pages
1538-1547
ISSN
  • 0013-7227 (ISSN-L)
  • 1945-7170
OpenAlex
W2166969890
Cited by
161
References
29
Citations by year
2026: 27 · 2025: 24 · 2024: 15 · 2023: 5 · 2022: 4 · 2021: 2 · 2020: 12 · 2019: 8 · 2018: 6 · 2017: 7 · 2016: 8 · 2015: 11 · 2014: 11 · 2013: 15 · 2012: 6
FWCI
11.03
Type
journal article
Language
en
Open access
Locations
  • Endocrinology (publishedVersion)
  • Europe PMC (PubMed Central) (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
National Cancer Institute (CA-72597, R01CA072597)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Cancer Diagnosis and Treatment
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Oncology › Neuroendocrine Tumor Research Advances
Keywords
GLP-1 receptor agonists, liraglutide, exenatide, RET proto-oncogene, calcitonin, mTOR signaling, type 2 diabetes
MeSH terms
Glucagon-Like Peptide-1 Receptor, Liraglutide, Animals, Calcitonin, Female, Immunohistochemistry, Ligands, Male, Models, Genetic, Phosphoproteins, Thyroid Gland, Time Factors, Signal Transduction, Receptors, Glucagon, Mice, Knockout, Proto-Oncogene Proteins c-ret, Mice, Glucagon-Like Peptide 1, TOR Serine-Threonine Kinases

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.